Cost-Effectiveness Analysis of Bendamustin-Rituximab Compared to Chop-Rituximab in the Treatment of Indolent Follicular Non-Hodgkin Lymhoma in the Czech Republic
Nov 1, 2014, 00:00
10.1016/j.jval.2014.08.2314
https://www.valueinhealthjournal.com/article/S1098-3015(14)04244-2/fulltext
Title :
Cost-Effectiveness Analysis of Bendamustin-Rituximab Compared to Chop-Rituximab in the Treatment of Indolent Follicular Non-Hodgkin Lymhoma in the Czech Republic
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(14)04244-2&doi=10.1016/j.jval.2014.08.2314
First page :
A641
Section Title :
Disease-Specific Studies
Open access? :
No
Section Order :
1770